Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of omidubicel-expanded umbilical cord blood transplantation in patients with severe aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJennifer FarrenGAGeorg Aue

Discussion

Loading...

Member takes

Overview

Phase II trial found omidubicel improves engraftment rates in severe aplastic anemia, with low graft versus host disease risk.

Key Points

  • This trial evaluates omidubicel as a treatment for severe aplastic anemia in patients lacking HLA-matched donors.
  • Single-center phase II trial enrolling SAA patients aged 4-60 years unresponsive to standard treatment.
  • Transplantation involved omidubicel and conditioning with anti-thymocyte globulin, cyclophosphamide, and total body irradiation.
  • Graft versus host disease was managed with tacrolimus and mycophenolate mofetil.
  • 94% of patients achieved neutrophil recovery in a median of 8 days and 89% had platelet recovery by day 24.
  • 94% of patients achieved sustained engraftment by day 100 and transfusion independence.
  • Low incidence of GVHD observed at 17%, with no grade III-IV acute GVHD.

Cite This Study

Farren et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db94https://doi.org/10.1182/blood-2025-5963
View Full Paper
Ask AI
Bookmark
Share